Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10567841			
Filing Date		2006-02-08			
First Named Inventor Franc		esc Dalmases			
Art Unit		2611			
Examiner Name					
Attorney Docket Number		DE030284			

				U.S.	PATENTS			Remove		
			Kind Code ¹				Pages,Columns,Lines where Relevant Passages or Releva Figures Appear			
	1	6049289		2000-04-11	WAGGAMON	ET AL				
	2	6356555	B1	2002-03-12	RAKIB ET AL					
If you wis	h to a	dd additional U.S. Pate	nt citatio	n information p	lease click the	Add button.	_	Add		
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date		faited Desument		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		
If you wis	1 h to a	dd additional U.S. Pub		•			d button			
						ENTE		Remove		
				FUREIGN PA	TENT DOCUM	T	1	Remove	umpo Lipao	
	Cite No	Foreign Document Number ³	Country Code ²	Kind	Publication	Name of Patente Applicant of cited Document	e or	Pages,Col where Rel	or Relevant	76
Examiner Initial*			Country	Kind	Publication	Name of Patente Applicant of cited	e or	Pages,Col where Rel Passages	evant or Relevant	76

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) E

EP

0103790

pplication Number		10567841
iling Date		2006-02-08
irst Named Inventor Franc		esc Dalmases
rt Unit		2611
xaminer Name		
ttornev Docket Number		DE030284

Date Considered

1984-03-28 PREISSINGER ET AL

	4	1204284	EP	A1	2000-07-21	WAKIZAKA		
	5	1229679	EP	A2	2002-08-07	HOFFMAN ET AL		
	6	2331207	GB	A	1999-05-12	SU-WON		
If you wis	h to a	d additional Foreign P	atent Document	citation	information pl	ease click the Add butto	Add	
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Cite Initiates Cite Cook, pure of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initiates Cite Cook, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								Ţ5
	1							

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a 1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document

If you wish to add additional non-patent literature document citation information please click the Add button Add EXAMINER SIGNATURE

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10567841
Filing Date		2006-02-08
First Named Inventor	Franc	esc Dalmases
Art Unit		2611
Examiner Name		
Attorney Docket Numb	ec	DE030284

CERTIFICATION STATEMENT

Diagra can	37	CFR .	1 97	and	1 02	to make	the	appropriate	colortion/s	٠ŀ٠

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 97 CFF 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(4)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Aaron M. Waxler/	Date (YYYY-MM-DD)	2007-02-08
Name/Print	Aaron Waxler	Registration Number	48.027

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Pleatert and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1445, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral purpuses for which the information is used by the U.S. Patient and Trademan Colline is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested region of the patient of the patient application of the patient application of the patient activities, which may result in farministion of proceedings or 4 anahoroment of the application of the patients of the pa

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.